The Latest Breaking News from Psoriasis

Ashling Armstrong says she gets people staring 'everyday' at her skin

Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses.  At week 16, patients receiving…

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1 2021. Q1 Financial Highlights

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously).  The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Damien Broderick, 30, said he woke up one day as a teenager and from his neck to his waist was "one big red, raw, flaky, scale"

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody.  Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…

Talented Danielle Robertson was diagnosed with psoriasis aged 16 and has endured crippling flare-ups ever since.